Biomx Inc. ( (PHGE) ) has released its Q3 earnings. Here is a breakdown of the information Biomx Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BiomX Inc. is a clinical-stage company specializing in the development of phage therapies targeting pathogenic bacteria, primarily in the healthcare sector. The company leverages its BOLT platform to create customized phage compositions for the treatment of chronic diseases with unmet needs.
In the third quarter of 2025, BiomX Inc. reported significant progress in its clinical programs and regulatory discussions with the FDA. The company received positive feedback on its BX011 program for diabetic foot infections and anticipates imminent FDA feedback on the clinical hold for its BX004 program targeting cystic fibrosis.
Key financial metrics for the quarter include a cash balance of $8.1 million, a decrease from $18 million at the end of 2024, primarily due to operating expenses. Research and development expenses decreased to $6.1 million from $7.3 million in the previous year, while general and administrative expenses also saw a reduction. The company reported a net loss of $9.2 million compared to a net income of $9.6 million in the same quarter last year.
Strategically, BiomX is focusing on advancing its BX011 program following FDA guidance, prioritizing diabetic foot infections as a lead indication. The company is also continuing patient enrollment for its BX004 program outside the U.S., with plans to report topline results in early 2026.
Looking ahead, BiomX is poised to continue its development efforts, with management expressing confidence in the potential of its phage therapies to address significant unmet medical needs. The company remains focused on securing necessary resources to advance its clinical programs.